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Allergen-specific T helper type 2 (Th2) responses followed by eosinophilic inflammation
of the lung are important causes of allergic asthma. Interleukin-5 (IL-5) is a master
regulator of eosinophil differentiation as well as activation. Blocking IL-5 using
monoclonal antibodies (mAbs) against IL-5 is a powerful way to improve asthmatic
symptoms in patients with an eosinophilic component of the disease. We have
previously shown that vaccination against IL-5 can abrogate eosinophilic inflammation of
the lung in allergic mice. More recently, we have demonstrated that eosinophil-mediated
skin disease in horses with insect bite hypersensitivity can be strongly reduced by
vaccination against IL-5. Here we would like to propose the development of a similar
vaccine for the treatment of asthma in humans.
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ASTHMA – A SIGNIFICANT CHRONIC RESPIRATORY DISEASE
THAT REPRESENTS A GROWING CHALLENGE
Asthma is a globally significant chronic respiratory disease with upward of 300 million patients
experiencing considerable morbidity ranging from occasional breathing difficulties (shortness of
breath, coughing, wheezing, and chest tightening) to more severe exacerbations (asthma attack)
requiring clinical interventions (Network, 2018). Inflammation in the lungs can be triggered
by a variety of non-specific stimuli such as cold air and exercise, as well as by allergens or
infectious microorganisms such as viruses. In turn, these events can activate a combination of
innate and adaptive immune responses and cellular inflammation, resulting in symptoms like
bronchial smooth muscle hyper-reactivity, excess mucus production from goblet cells within
epithelia, and potential for bronchial remodeling and airway narrowing. Given the remarkable
heterogeneity in both stimuli and responses, it is not surprising to see the involvement and overlap
of several distinct soluble mediators and cell types. Key amongst these are cytokines involved in
immunoglobulin isotype switching (IgE synthesis by IL-4), mast cell proliferation (IL-9), airway
hyper-responsiveness and mucus production (IL-13), and eosinophil inflammation (IL-5). In
addition to type 2 T helper cell (Th2) allergic responses, also Th1, Th17, and Th9 cellular subsets
have been implicated (Holgate and Polosa, 2008; Lambrecht and Hammad, 2015).
In many patients, the disease can be controlled by a combination of anti-inflammatory
immunosuppressants (such as inhaled corticosteroids) and by bronchodilators that relax
constricted airway smooth muscle (e.g., β2-adrenergic agonists). However, between 5–10% of
patients are refractory to corticosteroid treatments thus complicating management of their asthma
and often leading to serious exacerbations requiring hospital intervention. This has encouraged the
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development of several biological drug alternatives based on
monoclonal antibodies (mAbs) for those individuals where
conventional small molecule drugs have failed.
mAbs HAVE CHANGED THE WAY WE
TREAT CHRONIC DISEASES BY
ALLOWING THE TARGETING OF
PROTEIN-PROTEIN INTERACTIONS
OUTSIDE THE CELL
Generation of mAbs was described more than 40 years ago in
mice (Kohler and Milstein, 1975), and over the past 20 years,
the technology has started to change clinical practice (Cui
et al., 2017). In contrast to small molecular drugs, which
classically target intracellular proteins, enzymes, ion channels,
and G-coupled proteins, mAbs have allowed the blocking
of extracellular protein-protein interactions. They may inhibit
receptor–ligand interactions or specifically target cell surface
receptors. Blocking protein–protein interactions with high
specificity has made it possible to inhibit cytokines, chemokines
and growth factors implicated in otherwise intractable disease
conditions while targeting cell surface receptors is often followed
by antibody-dependent cellular cytotoxicity (ADCC) and is
generally used for the elimination of cancer cells. Due to these
unique properties, mAbs have become the most rapidly growing
revenue source for the pharmaceutical industry. The top-in-class
antibody Humira R© was the world’s best-selling drug 2015 with
annual global expenditure reaching US$14 billion. Moreover, 6
of the 10 biggest blockbuster drugs are mAbs1.
The flip-side of the argument is the high costs that are
associated with the generation of these biomolecules, cutting a
large fraction of the world’s population off from the benefits
brought by this new treatment modality. In addition, despite
mAbs high efficiency, treatment involves injections of very
substantial amounts of protein that may cause local side-effects
such as pain and irritation or even severe anaphylactic reactions.
An additional potential issue associated with the use of mAbs
is the induction of anti-drug antibodies that may neutralize or
eliminate the injected mAbs and may accelerate local or systemic
adverse events during injection (Steenholdt et al., 2011, 2012).
Many of these problems could be tackled by moving on from
the current passive vaccination strategies with mAbs to active
vaccination approaches that instruct the body to generate its own
antibody responses. Potential issues with this new approach are
that it may be difficult to (i) reach sufficient levels of antibodies
and (ii) the response may be less controllable; in particular, the
potential irreversibility of the induced antibody responses is an
obvious issue. However, recent developments in vaccine design,
genetics, and clinical research are converging to pave the way for
the clinical development of such auto-vaccines. It was recently
shown that anti-cytokine vaccination could reach critical levels
in humans (Lauwerys et al., 2014; Cavelti-Weder et al., 2016;
Ducreux et al., 2016) and other target species (Bachmann et al.,
1https://labiotech.eu/top-10-best-selling-biologicals-blockbusters-2015/
2018; Fettelschoss-Gabriel et al., 2018b), and that the induced
antibody responses are indeed reversible. The present review
will examine recent findings and outline how these findings
may be applied to the development of a vaccine against asthma
targeting IL-5.
HARNESSING THE IMMUNE SYSTEM:
HOW TO INDUCE SELF-SPECIFIC
ANTIBODY RESPONSES DIRECTED
AGAINST CYTOKINES
Long-lived IgG responses require activation of specific B as
well as (follicular) Th cells. However, the immune system is
usually tolerant to self-proteins, and induction of cytokine-
specific antibody responses, therefore, requires overcoming or
bypassing B cell as well as Th cell tolerance. In general, soluble
proteins do not cause B cell tolerance and antibody responses
against soluble self-proteins are usually controlled by Th cell
tolerance only (Adelstein et al., 1991). As a case in point, we have
recently shown that introduction of a single virus-derived Th cell
epitope into IL-1β was able to overcome B cell unresponsiveness
and immunization with this modified cytokine formulated in
adjuvants readily resulted in strong and specific IgG responses
(Spohn et al., 2014). Hence, linking cytokines to a source of Th
cell epitopes is able to drive specific B cell responses. This is
similar to classical carbohydrate conjugate vaccines where B cells
recognize the carbohydrate and Th cells recognize the carrier
protein to which the carbohydrates are linked (Mond et al., 1995)
(Figure 1A).
Conventional protein-cytokine conjugate vaccines have
struggled to induce sufficient levels of antibodies to reach clinical
efficacy (Ratsimandresy et al., 2009). Indeed, while the use of
strong adjuvants in preclinical experiments may help to increase
the efficiency in murine model diseases, translation to the clinic
is difficult, as such adjuvants cannot be used in humans. A case
in point is a vaccine against TNF (Dalum et al., 1999), which
successfully treated rheumatoid arthritis in mice but failed to
reach efficacy in humans. One reason for this failed translation
was the use of complete Freund’s adjuvants (CFA) in the murine
experiments, an adjuvant that under no circumstances could
be used in humans, due to the induction of local granuloma
or systemic reactogenicity, hypersensitization to mycobacteria
(tuberculin) and heightened risk of autoimmune disease.
Virus-like particles (VLPs) may offer an elegant solution to
this problem. By displaying cytokines on the surface of VLPs,
it is possible to induce high levels of neutralizing antibodies
without the use of adjuvants. Several factors account for the high
immunogenicity of antigens displayed on VLPs. One important
parameter is the repetitive display of the antigen, causing efficient
cross-linking of B cell receptors (BCRs) on B cells, constituting
a strong activation signal (Figure 1B). Also, repetitive epitopes
efficiently recruit components of the innate humoral immune
system in particular complement and natural IgM (Bachmann
and Jennings, 2010). This enhances B cell activation via CD21
and facilitates B cell-mediated antigen deposition on follicular
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FIGURE 1 | Schematic representation of intermolecular help for the induction of cytokine-specific antibody responses. (A) Cytokines are conjugated to a carrier
protein, resulting in cytokine-specific B cells receiving, however, carrier specific T-cell help. (B) Conjugation to virus-like particles (VLPs) further increases antibody
responses, due to repetitive display of the antigen and packaged non-coding RNA, which is a ligand for toll-like receptor 7/8 (TLR7/8) and present in many RNA
virus-derived VLPs. (C) Presence of a universal T cell epitope may further improve Th cell dependent IgG responses, in particular if the epitope is derived from
tetanus toxin (TT), as essentially everybody harbors memory Th cells against TT.
dendritic cells (FDCs), which present native antigen to B cells
(Link et al., 2012). Antigen on FDCs is essential for the formation
of germinal centers, which in turn are essential for the generation
of memory B and long-lived plasma cells (Liu et al., 1992).
Hence, the ability to recruit natural IgM and complement
greatly increases immunogenicity. An additional reason for the
strong immunogenicity of antigens displayed on VLPs is the
bacterial RNA packaged by many VLPs produced in bacteria.
RNA is a ligand for TLR7/8 and serves as “packaged adjuvant”
enhancing IgG as well as IgA responses (Jegerlehner et al.,
2007; Bessa et al., 2009; Hou et al., 2011) (Figure 1B). For this
reason, cytokines on the surface of VLPs can induce strong and
neutralizing antibody responses that show preclinical and clinical
efficacy. As an example, formulation of an IL-1β-VLP conjugate
vaccine in Alum was sufficient to induce neutralizing anti-IL-
1 antibodies in at least a fraction of human type II diabetes
patients (Cavelti-Weder et al., 2016). We have recently optimized
the immunogenicity of a VLP derived from the plant-specific
cucumber mosaic virus. By introducing a universal T cell epitope
derived from tetanus toxin, we generated a VLP optimized for
the elderly (CuMVTT) (Zeltins et al., 2017) since essentially all
individuals have been immunized multiple times against tetanus
and harbor specific memory Th cells (Figure 1C). Using this
CuMVTT, we have been able to treat atopic dermatitis in dogs
and horses by immunizing against IL-31 and IL-5, respectively
(Bachmann et al., 2018; Fettelschoss-Gabriel et al., 2018b). Hence,
cytokines displayed on VLPs hold promise to induce clinically
relevant antibody levels for the treatment of chronic diseases.
It is important to note that maintenance of T cell tolerance
for self-antigens is key, so vaccines targeting self-molecules
should avoid breaking tolerance completely. Otherwise, there
may be a risk of undesired auto-immune complications. An
important safety aspect of VLP-based vaccines is that they confer
self-antigens with repetitive presentation on their surface [an
immunogenic feature of many pathogens, also called pathogen-
associated structural pattern (PASP) (Bachmann and Jennings,
2010)]. Hence, VLPs place the self-antigen in an immunologically
active context and link it to T-cell help directed toward the
VLP carrier, features that are absent from endogenous self-
antigens (see Figure 1). Therefore, the B cells receive bystander
T cell help for the self-antigen only when coupled to the VLP,
whereas uncoupled self-antigens will not receive bystander T
cell help. Reassuringly in preclinical studies for psoriasis (a
chronic inflammatory skin disorder), a VLP-vaccine targeting
the pro-inflammatory cytokine IL-17, we demonstrated that
induced anti-IL-17 antibody levels reversed after cessation of
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immunization and stimulating an endogenous flare of the
cytokine using imiquimod (a TLR7/8 ligand and potent IL-17
activator) was unable to influence antibody responses, as T cell
help from the VLP was missing (Rohn et al., 2006; Zeltins et al.,
2017). This is fundamentally different from classical prophylactic
vaccines that are designed to trigger the immune system to
respond upon re-encountering the target pathogen.
ASTHMA AND THE ROLE OF IL-5
Allergic asthma is characterized by chronic inflammation of the
airways and manifests as episodes of airway obstruction and
wheezing. Roughly half of severe asthma clinical cases appear
to present with a non-allergic etiology. However, a key feature
for a subset of asthma patients is increased levels of granulocytes
called eosinophils, which are very toxic cells in the body (Yancey
et al., 2017). Chronic eosinophilic airway inflammation is a
particularly severe form of asthma, which eventually causes
structural changes of the airways. This disease progression is
summarized as airway remodeling that may result in bronchial
hyperresponsiveness to non-specific stimuli, a characteristic of
intrinsic (non-allergic) asthma (Cohn et al., 2004).
Standard therapies for asthma are non-specific and involve
corticosteroids and long- or short-acting β-adrenoceptor
agonists. These medications, however, only suppress symptoms
but fail to treat the underlying cause of the disease. Furthermore,
compliance is generally low, in particular for twice-daily
inhalation regimens (Bender et al., 1997; Onyirimba et al.,
2003). Non-specific immunotherapy using VLPs loaded with
a ligand for TLR9 is a promising option for the treatment of
asthma but requires further investigation (Beeh et al., 2013;
Rank et al., 2013). In contrast, specific immunotherapy (SIT)
represents a potential disease-modifying therapy that is, as the
name implies, more specific than the classical drugs (Nagata
and Nakagome, 2010). SIT, however, is only possible for a
limited number of allergens, time-consuming and cannot be
performed with patients suffering from severe asthma (Creticos,
1992; Walker et al., 1995). Drugs specifically interfering with
the allergic immune response are promising new alternatives.
A key cell type in asthma is the allergen-specific Th2 cells,
which produce IL-4, causing generation of IgE followed by
activation of mast cells. In addition, Th2 cells release IL-13,
increasing obstructing mucus production and IL-5, as well as
eotaxin, recruiting eosinophils. An alternative to the non-specific
standard therapy with corticosteroids or SIT, is therefore to
specifically target the cells and factors involved in asthma. Four
such FDA approved drugs are mAbs against IgE (Omalizumab),
IL-5 (Mepolizumab, Reslizumab) (Quirce et al., 2017), and
recently IL-5 receptor (Benralizumab) (Kupczyk and Kuna,
2018). Omalizumab neutralizes IgE and may even remove it from
mast cells. Hence, blocking IgE mostly results in reduced mast
cell activity, most important during the early asthma response. In
contrast, therapies blocking IL-5 aim at reducing blood and tissue
eosinophils thereby being more potent at halting later phases
of the response, including airway remodeling. Mepolizumab,
Reslizumab, and Benralizumab are therefore mostly used
for the treatment of severe eosinophilic asthma, a chronic
condition requiring life-long treatment. GlaxoSmithKline (GSK)
is currently negotiating with the authorities for approval of
Mepolizumab in chronic obstructive pulmonary disease (COPD)
subsequent to a successful phase III study in the indication
(Pavord et al., 2017). Nonetheless, adverse reactions such as
urticaria, anaphylaxis or serum sickness have been reported with
passive administration of antibodies and repeated injections
are required to maintain effectiveness. With an excellent safety
profile (Leung et al., 2017) and the requirement for long-term
if not life-long treatment, IL-5 might be an ideal target for the
development of an active vaccine against asthma and potentially
COPD.
PRECLINICAL AND CLINICAL DATA
SUPPORTING THE DEVELOPMENT OF A
VACCINE AGAINST IL-5
IL-5 is a soluble low abundant protein and tolerance at the
B cell level may therefore not be expected (Bachmann and
Dyer, 2004). Indeed, the coupling of IL-5 to VLPs derived from
the bacteriophage Qβ readily induced strong and neutralizing
antibody responses in mice in the absence of an adjuvant (Zou
et al., 2010). Neutralizing antibodies were able to reduce numbers
of eosinophils in peripheral blood and reduced eosinophil
infiltration in the lung of asthmatic mice by more than 95%.
Hence, vaccination against IL-5 resulted in protection against
eosinophilic infiltration, the same principal biological effect
observed for commercial anti IL-5 antibody therapies. Similar
observations have been made with a DNA based vaccine
(Hertz et al., 2001). DNA vaccines, however, are usually not
immunogenic in humans and therefore difficult to translate
into clinical application. More recently, we have demonstrated
that VLP-based vaccines are efficacious in a more real-life
setting, namely insect bite hypersensitivity (IBH) in horses.
IBH is an allergic response to bites of midges (Culicoides)
and results in strong inflammation of the skin by eosinophils.
Similarly as seen in allergic asthma in humans (Price et al.,
2016), blood eosinophil counts correlated with disease severity
(Fettelschoss-Gabriel et al., 2018b). In a double-blind, placebo-
controlled study, IBH horses were immunized against IL-5
using a conjugate vaccine consisting of IL-5 conjugated to the
immune optimized CuMVTT-VLP (Zeltins et al., 2017). IBH is
caused by insect-bites and therefore seasonal with no symptoms
during the winter. Horses were vaccinated with IL-5-CuMVTT
in the absence of adjuvants before and during the season. The
vaccine was well tolerated with no signs of adverse events after
repeated doses, and no difference in helminth burden could
be detected. Strikingly, symptoms of IBH in immunized horses
were strongly reduced compared to the previous untreated
season of the same horses as well as to the placebo horses
(Fettelschoss-Gabriel et al., 2018b). Anti-IL-5 responses declined
in all horses with defined half-lives of a few months and thus
were reversible. More recently, we have shown that horses
can be immunized over multiple seasons and that protection
against IBH remains stable (Fettelschoss-Gabriel et al., 2018a).
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Hence, vaccination of horses against IL-5 results in strong
protection against IBH, an eosinophil-mediated inflammatory
disease. By analogy, we are confident that a human version
of the vaccine will protect against severe asthma, with
an eosinophil-mediated pathology for the disease of the
lung.
CONCLUSION
IL-5 is an excellent target for the treatment of allergic and non-
allergic asthma with an eosinophilic component. We propose to
develop a vaccine against IL-5 for the treatment of asthma in
humans to broaden patient access to the highly effective therapy
and to facilitate long-term treatment.
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